huCD19/huBCMA Mouse
제품명
huCD19/huBCMA Mouse
제품 ID
C001993
품종 계통
C57BL/6NCya-Cd19em3(hCD19)Tnfrsf17em1(hTNFRSF17)/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “huCD19/huBCMA Mouse (카탈로그 번호 C001993)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
유전자 별칭
BCM, BCMA, CD269, TNFRSF13A, B4, CVID3
염색체
Chr 16, Chr 16
MGI ID
Datasheet
품종 계통 설명
CD19 is predominantly expressed throughout B-cell development and serves as a critical co-receptor for B-cell receptor (BCR) signal transduction, participating in B-cell development, activation, and differentiation [1]. The TNFRSF17 gene encodes B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily. BCMA is primarily expressed on mature B cells and plasma cells and acts as a key regulator for maintaining plasma cell survival, antibody secretion, and humoral immunity [2-3].
The huCD19/huBCMA(TNFRSF17) mouse is a dual-gene humanized model obtained by crossing the huCD19 mouse (Catalog No.: C001731) with the huBCMA(TNFRSF17) mouse (Catalog No.: C001630). These two targets cover the critical stages of B-cell development and plasma cell maturation, respectively, together forming an important regulatory network for B-cell immune responses. This model can be used to study the mechanisms of B-cell development, differentiation, and humoral immunity regulation, as well as B-cell-related autoimmune diseases and malignancies such as systemic lupus erythematosus (SLE) and multiple myeloma (MM). It is also suitable for the screening, pharmacodynamic evaluation, safety assessment, and mechanism-of-action studies of anti-CD19 and anti-BCMA dual-target drugs, CAR-T cell therapies, bispecific antibodies, and combination treatment strategies, providing an ideal preclinical research platform for the development of innovative therapies for B-cell-related diseases.
Reference
Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012 Nov 29;1(1):36.
Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020 Sep 17;13(1):125.
Coquery CM, Erickson LD. Regulatory roles of the tumor necrosis factor receptor BCMA. Crit Rev Immunol. 2012;32(4):287–305.
변형 전략
The huCD19/huBCMA mouse is a dual-gene humanized model obtained by crossing the huCD19 mouse (Catalog No.: C001731) with the huBCMA(TNFRSF17) mouse (Catalog No.: C001630).
Figure 1. Gene editing strategy of huCD19 mice. The sequences from the start codon to partial intron 4 of the mouse Cd19 gene were replaced with the sequences from the start codon to partial intron 4 of the human CD19 gene.
Figure 2. Gene editing strategy of huBCMA(TNFRSF17) mice. The mouse Tnfrsf17 endogenous extracellular domain was replaced with the human TNFRSF17 extracellular domain.
응용 분야
Research on the regulatory mechanisms of B-cell development, differentiation, and humoral immunity;
Research on B-cell-related autoimmune diseases and malignancies such as systemic lupus erythematosus (SLE) and multiple myeloma (MM);
Research on the screening, pharmacodynamic evaluation, safety evaluation, and mechanism of action of dual-target drugs against CD19 and BCMA, CAR-T cell therapy, bispecific antibodies, and combination therapy strategies.
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.